These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 6594782)
1. [VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults]. Marín P; Grañena A; Carreras E; Sierra J; Olivé MT; Rozman C Sangre (Barc); 1984; 29(4-A):399-404. PubMed ID: 6594782 [No Abstract] [Full Text] [Related]
2. VM-26 and cytarabine combination chemotherapy in refractory or relapsed adult acute lymphoblastic leukemia. Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Risso M; Vimercati R; Cerri R; Rossi E Haematologica; 1984; 69(6):747-51. PubMed ID: 6441752 [No Abstract] [Full Text] [Related]
3. [Treatment of acute refractory lymphoblastic leukemia in the adult with VM-26 and ARA-C]. Rafecas FJ; Sanz MA Sangre (Barc); 1984; 29(6):1052-3. PubMed ID: 6598235 [No Abstract] [Full Text] [Related]
4. [Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase]. Martín-Aragonés G; Sanz MA; Martínez JA; Rafecas FJ; Gomis F; Lorenzo I; Sanz G; Marty ML Sangre (Barc); 1985; 30(1):15-21. PubMed ID: 3859023 [No Abstract] [Full Text] [Related]
5. Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia. Hoelzer D; Thiel E; Löffler H; Büchner T; Ganser A; Heil G; Kurrle E; Heimpel H; Koch P; Lipp T Semin Oncol; 1987 Jun; 14(2 Suppl 1):92-7. PubMed ID: 3473688 [No Abstract] [Full Text] [Related]
6. Teniposide and cytarabine combination chemotherapy in the treatment of relapsed adolescent and adult acute lymphoblastic leukemia. Sanz GF; Sanz MA; Rafecas FJ; Martínez JA; Martín-Aragonés G; Marty ML Cancer Treat Rep; 1986 Nov; 70(11):1321-3. PubMed ID: 3464352 [TBL] [Abstract][Full Text] [Related]
7. [Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias]. Navajas Gutiérrez A; Bezanilla Regato JL; Moya Calderón E; Piñán MA An Esp Pediatr; 1988 Oct; 29 Suppl 34():91-3. PubMed ID: 3214046 [No Abstract] [Full Text] [Related]
8. Teniposide (VM-26) and ara-C in the treatment of adult acute lymphoblastic leukemia. Linker CA; Levitt LJ; O'Donnell M; Ries CA; Forman SJ Semin Oncol; 1987 Jun; 14(2 Suppl 1):78-85. PubMed ID: 3473686 [No Abstract] [Full Text] [Related]
9. Treatment of refractory acute lymphoblastic leukemia with teniposide and cytarabine. Kamen BA; Casper J; Lauer S; Camitta BM; Holcenberg JS Cancer Treat Rep; 1986 Jul; 70(7):935-6. PubMed ID: 3459577 [No Abstract] [Full Text] [Related]
10. [Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone]. Marín P; Grañena A; Carreras E; Ribera JM; Rozman C Sangre (Barc); 1984; 29(6):987-92. PubMed ID: 6598237 [No Abstract] [Full Text] [Related]
11. Severe hypertensive reactions to teniposide (VM-26) in infants with congenital leukemia. Shimizu H; Frankel LS; Culbert SJ Am J Pediatr Hematol Oncol; 1987; 9(3):239-41. PubMed ID: 3479027 [TBL] [Abstract][Full Text] [Related]
12. The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia. Rivera GK J Clin Oncol; 1988 Feb; 6(2):191-3. PubMed ID: 3276820 [No Abstract] [Full Text] [Related]
13. Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases. Grem JL; Hoth DF; Leyland-Jones B; King SA; Ungerleider RS; Wittes RE J Clin Oncol; 1988 Feb; 6(2):351-79. PubMed ID: 3276827 [TBL] [Abstract][Full Text] [Related]
14. VM26 therapy in children with drug-refractory lymphocytic leukemia. Rivera G; Dahl GV; Murphy SB; Bowman WP; Aur RJ; Avery TL; Simone JV Cancer Chemother Pharmacol; 1982; 7(2-3):169-72. PubMed ID: 7083458 [No Abstract] [Full Text] [Related]
15. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia. Rosenstock JG; Donaldson MH Cancer Treat Rep; 1976 Mar; 60(3):265-7. PubMed ID: 1063066 [No Abstract] [Full Text] [Related]
16. [A case of refractory acute lymphocytic leukemia responded to an intermediate-dose of cytosine arabinoside (ID Ara-C) therapy]. Hirota Y; Shibuya T; Ohhara N; Okamura S; Iwagiri R; Tada Y; Otsuka T; Nagano M; Tsuda Y; Niho Y Rinsho Ketsueki; 1986 Jun; 27(6):941-6. PubMed ID: 3463812 [No Abstract] [Full Text] [Related]
17. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group. Bleyer WA; Krivit W; Chard RL; Hammond D Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a polychemotherapeutic regimen including Idarubicin (4-demethoxydaunorubicin) in relapsed acute lymphocytic leukemia. Mandelli F; Testi AM; Aloe Spiriti MA; Giona F; Meloni G; Moleti ML; Amadori S; Pacciarini MA Haematologica; 1986; 71(1):34-8. PubMed ID: 3084353 [No Abstract] [Full Text] [Related]
19. [High-dose cytosine arabinoside and L-asparaginase in the treatment of refractory or recurrent acute non-lymphoblastic leukemia]. Sanz MA; Borrego D; Martín-Aragonés G; Martínez JA; Lorenzo I; Sanz G; Sayas MJ; Jarque I; Pastor E; Rafecas J Sangre (Barc); 1987; 32(4):476-81. PubMed ID: 3660187 [No Abstract] [Full Text] [Related]
20. Short courses of cytosine arabinoside and L-asparaginase in children with acute leukemia. Ekert H; Colebatch JH; Matthews RN Cancer; 1972 Sep; 30(3):643-7. PubMed ID: 4507080 [No Abstract] [Full Text] [Related] [Next] [New Search]